Elanco Animal Health Incorporated reported first quarter 2025 financial results on May 7, 2025, exceeding its guidance for revenue, adjusted EBITDA, and adjusted EPS. The company achieved 4% organic constant currency revenue growth, with Pet Health trends accelerating in March and April, and strong execution in Farm Animal.
Net income for the quarter was $67 million, a 109% increase from Q1 2024, and adjusted EPS was $0.37, up 9% year-over-year. Adjusted EBITDA for Q1 2025 was $276 million, a 6% decrease compared to Q1 2024, but still above guidance. The company's net leverage ratio was 4.4x adjusted EBITDA as of March 31, 2025, with the year-end target improved to 3.9x to 4.3x due to disciplined working capital management, favorable currency rates, and the lotilaner U.S. royalty monetization.
Elanco raised its full-year 2025 revenue guidance to $4,510 million to $4,580 million, primarily due to a favorable foreign exchange tailwind, while maintaining its adjusted EBITDA and adjusted EPS guidance. The innovation revenue target for 2025 was also increased to $660 million to $740 million, driven by the commercialization of potential blockbuster products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.